all news stories

Eligo Bioscience Raises $30 Million To Write a Novel Chapter for Genetic Medicines

The Series B round has been led by Sanofi Ventures with participation from new investor Bpifrance (through its InnoBio 2 fund), and existing investors Khosla Ventures and Seventure Partners. The funding is expected to generate proof of concept clinical data in patients.